Evidence map›Paper›PMID 34387713›Full record

ReviewZeitschrift fur Rheumatologie2021

[Medications when travelling with underlying inflammatory rheumatic disease].

K Rose, C Iking-Konert

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

K RoseIII. Medizinische Klinik, Sektion Rheumatologie, Zentrum für Innere Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. k.rose@uke.de.ORCID http://orcid.org/0000-0002-3225-0384
C Iking-KonertIII. Medizinische Klinik, Sektion Rheumatologie, Zentrum für Innere Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Travelling poses particular challenges for patients with rheumatic diseases. This article provides specific guidance on how best to manage medication while away from home. Besides outlining advice on basic logistic issues, such as the transportation, importation and storage of drugs, the article concentrates on travelling while receiving immunosuppressive therapy and carrying narcotics. Especially when transporting narcotics, travel requires careful planning in advance in close collaboration with physicians on account of the strict and internationally diverse import restrictions on controlled substances. While travelling, all drugs should be kept in the original packaging, including the package insert and stored in carry-on luggage. A specific medical passport may be needed. Immunosuppressive and narcotic drugs require medical certificates issued by the prescribing physician, which may need to be certified by the responsible national agencies. Patients receiving glucocorticoid treatment who travel in or across multiple time zones should also be aware of how the medication impacts and interacts with circadian rhythms so as to optimize the anti-inflammatory effects of the drugs and to avoid unnecessary complications. Given the significant discrepancies in medical care and availability of medication worldwide, the article further stresses the importance of a comprehensive medical kit tailored to the patient's individual medicinal needs. Finally, as immunocompromised travellers are at increased risk of infections, advice is given on the use of anti-infective drugs and chemoprophylaxis for patients travelling to areas in which malaria is endemic as well as on their possible interactions with immunosuppressive treatment.

Indexed as

MalariaRheumatic DiseasesHumansImmunocompromised HostTravelCircadian rhythmControlled substancesImmunosuppressivesMedical kitTravel medicine

Identifiers

PMID34387713
OpenAlexW3190777331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.